<qa>  What was the first year phase of the study?Study NCT00055497 was designed to evaluate the efficacy and safety of adalimumab in the maintenance of clinical remission in patients with Crohns disease CD. The study consisted of 2 phases: 1. the first year phase lasting until Week 56 and consisting of a randomized, double-blind DB, placebo-controlled portion NCT00055497 and of a concomitant open label OL portion, and 2. a long-term extension phase NCT01070303 that lasted 264 additional weeks Week 56 to Week 320. 